Mirum Pharmaceuticals, Inc.

MIRMNASDAQHealthcare● Active

$91.97

$-1.51(-1.62%)

Market Cap$4.6B

P/E Ratio—

52W High$114.99

52W Low$43.5

Avg Volume985K

Open$95.44

Beta0.51

Overview

Mirum Pharmaceuticals, Inc. (MIRM) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

MIRM · free cash flow · updated Jun 8, 2026

Core FCF metrics

MIRM · FCF · TTM · margin & CAGR

Free cash flow was $54.9M for FY2025 (fiscal year ending 2025-12-31), up 488.0% year-over-year The FCF margin was 10.5%.

FY2025 Free Cash Flow$54.9M▲ +488.0% YoY

Trailing 12M (TTM)−$172.6MTrailing 4Q sum · TTM negative vs latest FY positive

FCF Margin10.5%$54.9M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

MIRM · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$55.8M(1M)$54.9M▲ +488.0%10.5%

FY2024$10.3M(1M)$9.3M▲ +110.2%2.8%

FY2023−$70.9M(20M)−$91.1M▲ +24.4%-48.9%

FY2022−$120.1M(0M)−$120.4M▲ +20.7%-156.3%

FY2021−$132.8M(19M)−$151.8M▼ 70.0%-793.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

MIRM · P/FCF · FCF yield · FCF per share

Mirum Pharmaceuticals, Inc. (MIRM) valuation ratios are currently unavailable — market cap, share count, or TTM data could not be retrieved from our data provider.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

Valuation ratios are unavailable — market cap, share count, or TTM data could not be retrieved. Individual metrics are shown where available.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

MIRM · cash flow statement · operating / investing / financing

For FY2025, Mirum Pharmaceuticals, Inc. generated $55.8M in operating cash flow and spent 1M in capital expenditures, yielding $54.9M in free cash flow.

Operating Activities

+$55.8M

Cash from core business operations

2025-12-31

Investing Activities

−$24.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$40.1M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($55.8M) − |CapEx| (1M) = FCF ($54.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

MIRM vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Mirum Pharmaceuticals, Inc.YOU

MIRM

$54.9M+488.0%10.5%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Mirum Pharmaceuticals, Inc. (MIRM) reported free cash flow of $54.9M for FY2025 (fiscal year ending 2025-12-31), up 488.0% year-over-year. The FCF margin was 10.5%.

Based on available data, Mirum Pharmaceuticals, Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $54.9M in FY2025.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

MIRM free cash flow · 8 questions

Mirum Pharmaceuticals, Inc. free cash flow was $54.9M for FY2025, up 488.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$172.6M.

MIRM free cash flowMIRM FCFMIRM FCF 2025MIRM free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Mirum Pharmaceuticals, Inc. · Mirum Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026